PHA Pharmagest Interactive SA

EQUASENS ANNOUNCES ITS 2026 FINANCIAL CALENDAR

EQUASENS ANNOUNCES ITS 2026 FINANCIAL CALENDAR

Villers-lès-Nancy, December 10, 2026, 6:00 p.m. CET – Equasens (ISIN: FR 0012882389 – Ticker: EQS), a leader in digital solutions for healthcare professionals, announces its financial calendar for the 2026 financial year.

EventsDates
2025 annual revenueFebruary 5, 2026 (after market close)
2025 annual resultsMarch 30, 2026 (before market opens)
2026 Q1 revenueApril 29, 2026 (after market close)
Annual General MeetingJune 25, 2026
2026 Half-year revenueJuly 30, 2026 (after market close)
2026 Half-year resultsSeptember 28, 2026 (before market opens)
2026 Q3 revenueOctober 29, 2026 (after market close)



About the Equasens Group

Founded over 35 years ago, Equasens Group, a leader in digital healthcare solutions, today employs over 1.400 people across Europe.         

Equasens Group’s specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as data hosting, financing and training adapted to their specific needs.         

And reflecting the spirit of its tagline "Technology for a More Human Experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient and secure healthcare system.

Listed on Euronext Paris™ - Compartment B Indices: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable by inclusion        .

Listed on Euronext Tech Leaders and the European Rising Tech label Eligible for the Deferred Settlement Service (SRD) and the PEA-PME scheme. ISIN: FR 0012882389 – Ticker symbol: EQS

Find all the latest news about the Equasens Group at and on LinkedIn

Contact

EQUASENS Group

Investor Relations



Chief Financial Officer: Frédérique SCHMIDT

Tel.: +33 (0)3 83 15 90 67

NewCap

Investor Relations

Thomas Grojean

Louis-Victor Delouvrier

Tel: +33 (0)1 44 71 94 94

NewCap

Financial Media Relations

Nicolas Mérigeau

Tel: +33 (0)1 44 71 94 94

Attachment



EN
10/12/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharmagest Interactive SA

 PRESS RELEASE

Strong commercial performance in 2025: Annual Recurring Revenue (ARR) ...

Strong commercial performance in 2025: Annual Recurring Revenue (ARR) of €108.0m (+8.8% as reported on 31 December 2025) and full-year revenue of €236.5m (+9.1% as reported) Villers-lès-Nancy, 05 February 2026 - 6:00 PM (CET) PRESS RELEASE Strong commercial performance in 2025: Annual Recurring Revenue (ARR) of €108.0m (+8.8% as reported on 31 December 2025) and full-year revenue of €236.5m (+9.1% as reported) First disclosure of Annual Recurring Revenue (ARR), reaching €108.0m at 31 December 2025, up a robust 8.8% year on yearGrowth driven by all business divisions, with particularly...

 PRESS RELEASE

Solides performances commerciales en 2025 : revenu annuel récurrent (A...

Solides performances commerciales en 2025 : revenu annuel récurrent (ARR) de 108,0 M€ (+8,8% en publié au 31/12/25) et chiffre d’affaires annuel de 236,5 M€ (+9,1% en publié) Villers-lès-Nancy, le 5 février 2026 - 18h00 (CET) COMMUNIQUE DE PRESSE Solides performances commerciales en 2025 : revenu annuel récurrent (ARR) de 108,0 M€ (+8,8% en publié au 31/12/25) et chiffre d’affaires annuel de 236,5 M€ (+9,1% en publié) Première publication de l’indicateur ARR, qui s’établit à 108,0 M€ au 31/12/25, en hausse dynamique de +8,8% vs. 2024Contribution de l’ensemble des segments d’activité e...

Jeremy Garnier
  • Jeremy Garnier

ODDO : Will small caps sustain their rebound in 2026?

The market environment now appears more favourable for small caps (solid growth prospects, consistent valuations) and the rebound seen in this asset class in 2025 could continue into 2026. After a stellar performance of 32.2% (+16.3 points vs MSCI Europe Smallcaps) from our ODDO BHF European Nextcap list in 2025, we are revising our H1 2026 Nextcap top pick list, which now includes: Comet, Corbion, Equasens, Jacquet Metals, Jost-Werke, PVA Tepla, Rosenbauer, Steyr Motors, Thermador Groupe and Wa...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch